GRI Bio (GRI)

• Market cap: $6.21M
• 1 day: -3.51%
• 5 days: -6.08%
• 1 month: -7.80%
• 3 months: -47.35%
• 6 months: -57.10%
• Year to date: -18.24%
• 1 year: -97.37%
• 5 years: -99.91%
• 10 years: -99.91%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Employees: 4

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

40% more funds holding

Funds holding: 5 [Q2] → 7 (+2) [Q3]

9.57% less ownership

Funds ownership: 14.27% [Q2] → 4.7% (-9.57%) [Q3]

64% less capital invested

Capital invested by funds: $140K [Q2] → $49.7K (-$90K) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10 1,339% upside
• Avg. target: $11.50 1,555% upside
• High target: $13 1,771% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis 30% 1-year accuracy 118 / 399 met price target	1,339% upside $10	Buy Initiated	9 Dec 2024
Ascendiant Capital Edward Woo 46% 1-year accuracy 31 / 68 met price target	1,771% upside $13	Buy Maintained	5 Dec 2024